Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulating Formularies: OIG Wants Closer Scrutiny of Process; CMS Says Focus on Results

This article was originally published in RPM Report

Executive Summary

The HHS Inspector General is concerned about lax oversight of conflict-of-interest standards on formulary committees for Medicare Part D plans. CMS is defending its approach, which emphasizes review of the formularies themselves, rather than the process to construct them. For biopharma companies, the “right” regulatory model for formulary oversight is an important issue as health care reform evolves.


Related Content

A Balancing Act: The Politics of Formularies
Medicare P&T Committees Can Consider Costs, But Only In Broad Context
P&T Committees Would Be Powerful Force Under Medicare Rx





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts